Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Liminatus Pharma ( (LIMN) ).
Liminatus Pharma has entered into a Memorandum of Understanding to form a research and development consortium with Samda Biolab and INNOCS AI to advance a novel blood-based diagnostic kit for early detection of pancreatic cancer. This strategic partnership aims to leverage the strengths of each company to deliver innovation in oncology diagnostics, with Liminatus Pharma leading the regulatory approval process and overseeing the acquisition of clinical datasets. The global pancreatic cancer diagnostics market is projected to reach $3 billion by 2026, offering Liminatus Pharma a significant opportunity for market leadership.
More about Liminatus Pharma
Liminatus Pharma, Inc. operates in the precision oncology diagnostics industry, focusing on developing innovative diagnostic solutions for cancer detection. The company is involved in creating a blood-based diagnostic kit for early detection of pancreatic cancer, aiming to enhance corporate value and establish a foothold in the metabolomics-driven cancer diagnostics market.
Average Trading Volume: 320,553
Technical Sentiment Signal: Buy
Current Market Cap: $269.3M
Find detailed analytics on LIMN stock on TipRanks’ Stock Analysis page.